Literature DB >> 8091148

Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis.

A Maccagno1, E Di Giorgio, E J Roldan, L E Caballero, A Perez Lloret.   

Abstract

Continuous oral pamidronate (APD), 1000 mg/day, was administered to 14 patients with rheumatoid arthritis. A control group of 13 patients with similar conditions received placebo under a double blind randomized study design. Periarticular erosion scores were significantly higher in the control group after 12 months treatment. This was attributed to a deterioration in this group rather than to an improvement in the APD treated one. By contrast, intraarticular narrowing score was not influenced by APD. Tolerance to oral APD was acceptable in all patients.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8091148     DOI： 10.3109/03009749409103063

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN： 0300-9742            Impact factor:   3.641


  11 in total

1.  Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT.

Authors:  Ryosuke Tsutsumi; Colleen Hock; C Dustin Bechtold; Steven T Proulx; Susan V Bukata; Hiromu Ito; Hani A Awad; Takashi Nakamura; Regis J O'Keefe; Edward M Schwarz
Journal:  J Orthop Res       Date:  2008-10       Impact factor: 3.494

2.  Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts.

Authors:  Mizuho Kittaka; Kotoe Mayahara; Tomoyuki Mukai; Tetsuya Yoshimoto; Teruhito Yoshitaka; Jeffrey P Gorski; Yasuyoshi Ueki
Journal:  J Bone Miner Res       Date:  2017-11-02       Impact factor: 6.741

3.  Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice.

Authors:  M Nakamura; T Ando; M Abe; K Kumagai; Y Endo
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

4.  Incadronate disodium inhibits joint destruction and periarticular bone loss only in the early phase of rat adjuvant-induced arthritis.

Authors:  Tomoyuki Akiyama; Satoshi Mori; Tasuku Mashiba; Kensaku Miyamoto; Satoshi Komatsubara; Yongping Cao; Takeshi Manabe; Hiromichi Norimatsu; Hiroaki Dobashi; Michiaki Tokuda
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

5.  The protective effects of incadronate on inflammation and joint destruction in established rat adjuvant arthritis.

Authors:  Hongpu Zhao; Shangli Liu; Dongsheng Huang; Qiuyu Xu; Toshihide Shuto; Yukihide Iwamoto
Journal:  Rheumatol Int       Date:  2005-10-20       Impact factor: 2.631

6.  A pilot trial of intravenous pamidronate for chronic low back pain.

Authors:  Marco Pappagallo; Brenda Breuer; Hung-Mo Lin; James B Moberly; Julia Tai; Christopher Noto; Angela Sanchez; Paolo L Manfredi
Journal:  Pain       Date:  2013-09-21       Impact factor: 6.961

Review 7.  Management of spondyloarthropathy: new pharmacological treatment options.

Authors:  Ruth Z Lee; Douglas J Veale
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  Anti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis.

Authors:  E M Schwarz; R J Looney; R J O'Keefe
Journal:  Arthritis Res       Date:  2000-03-27

9.  A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis.

Authors:  Benoit Le Goff; Elise Soltner; Céline Charrier; Yves Maugars; Françoise Rédini; Dominique Heymann; Jean-Marie Berthelot
Journal:  Arthritis Res Ther       Date:  2009-12-10       Impact factor: 5.156

Review 10.  Clinical development of anti-RANKL therapy.

Authors:  Edward M Schwarz; Christopher T Ritchlin
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.